keyword
MENU ▼
Read by QxMD icon Read
search

quetiapine metabolic

keyword
https://www.readbyqxmd.com/read/29730938/continuation-of-atypical-antipsychotic-medication-during-early-pregnancy-and-the-risk-of-gestational-diabetes
#1
Yoonyoung Park, Sonia Hernandez-Diaz, Brian T Bateman, Jacqueline M Cohen, Rishi J Desai, Elisabetta Patorno, Robert J Glynn, Lee S Cohen, Helen Mogun, Krista F Huybrechts
OBJECTIVE: Some atypical antipsychotics are associated with metabolic side effects, which are risk factors for gestational diabetes. The authors examined the risk of developing gestational diabetes associated with the continuation of treatment with aripiprazole, ziprasidone, quetiapine, risperidone, and olanzapine during pregnancy compared with discontinuation of these antipsychotic drugs. METHOD: Nondiabetic pregnant women who were linked to a live-born infant and enrolled in Medicaid (2000-2010) and who received one or more prescriptions dispensed for an antipsychotic drug during the 3 months before pregnancy were included in the analyses...
May 7, 2018: American Journal of Psychiatry
https://www.readbyqxmd.com/read/29702137/reduced-clearance-of-venlafaxine-in-a-combined-treatment-with-quetiapine
#2
Michael Paulzen, Georgios Schoretsanitis, Christoph Hiemke, Gerhard Gründer, Ekkehard Haen, Marc Augustin
Venlafaxine and the atypical antipsychotic quetiapine are often administered concomitantly. Both drugs share several metabolic hepatic pathways. However, pharmacokinetic interactions between venlafaxine and quetiapine have not been studied yet. A therapeutic drug monitoring database containing serum concentrations of venlafaxine (VEN) and its active metabolite O-desmethylvenlafaxine (ODVEN) was analyzed. Two groups of patients were compared: venlafaxine monotherapy V0 (n = 153) and co-medication with quetiapine, VQUE (n = 71)...
April 24, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29536616/canadian-network-for-mood-and-anxiety-treatments-canmat-and-international-society-for-bipolar-disorders-isbd-2018-guidelines-for-the-management-of-patients-with-bipolar-disorder
#3
Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, Ayal Schaffer, David J Bond, Benicio N Frey, Verinder Sharma, Benjamin I Goldstein, Soham Rej, Serge Beaulieu, Martin Alda, Glenda MacQueen, Roumen V Milev, Arun Ravindran, Claire O'Donovan, Diane McIntosh, Raymond W Lam, Gustavo Vazquez, Flavio Kapczinski, Roger S McIntyre, Jan Kozicky, Shigenobu Kanba, Beny Lafer, Trisha Suppes, Joseph R Calabrese, Eduard Vieta, Gin Malhi, Robert M Post, Michael Berk
The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments...
March 2018: Bipolar Disorders
https://www.readbyqxmd.com/read/29501386/associations-between-clinical-and-psychosocial-factors-and-metabolic-and-cardiovascular-risk-factors-in-overweight-patients-with-schizophrenia-spectrum-disorders-baseline-and-two-years-findings-from-the-change-trial
#4
Ane Storch Jakobsen, Helene Speyer, Hans Christian Brix Nørgaard, Carsten Hjorthøj, Jesper Krogh, Ole Mors, Merete Nordentoft
OBJECTIVES: People with severe mental disorders die averagely 15years earlier than people in the Western background population, cardiovascular disease being the most frequent cause of death with unhealthy eating habits and lower levels of physical activity as major contributing risk factors. Understanding possible associations and predictors of the specific cardiovascular risk may permit more targeted and effective prevention. The aim of this study was to investigate the associations between clinical and psychosocial factors and several separate cardiovascular risk factors in a cohort of 428 persons with schizophrenia and abdominal obesity enrolled in the CHANGE trial...
February 28, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29477703/latent-toxoplasma-gondii-infection-is-associated-with-decreased-serum-triglyceride-to-high-density-lipoprotein-cholesterol-ratio-in-male-patients-with-schizophrenia
#5
Marina Sagud, Suzana Vlatkovic, Dubravka Svob Strac, Mario Sviben, Maja Zivkovic, Maja Vilibic, Bjanka Vuksan-Cusa, Alma Mihaljevic-Peles, Nela Pivac
BACKGROUND: Previous studies suggested a complex association between Toxoplasma gondii (TG) infection and host lipid metabolism. Both TG infection and metabolic disturbances are very common in patients with schizophrenia, but this relationship is not clear. METHODS: In this cross-sectional study, we evaluated the association between TG seropositivity, serum lipid levels, body mass index (BMI) and metabolic syndrome (MetS) in 210 male inpatients with schizophrenia...
April 2018: Comprehensive Psychiatry
https://www.readbyqxmd.com/read/29471411/mechanisms-underpinning-the-polypharmacy-effects-of-medications-in-psychiatry
#6
Chiara C Bortolasci, Briana Spolding, Edward Callaly, Sheree Martin, Bruna Panizzutti, Srisaiyini Kidnapillai, Timothy Connor, Kyoko Hasebe, Mohammadreza Mohebbi, Olivia M Dean, Sean L McGee, Seetal Dodd, Laura Gray, Michael Berk, Ken Walder
Background: Bipolar disorder (BD) is a mental health condition with progressive social and cognitive function disturbances. Most patients' treatments are based on polypharmacy, but with no biological basis and little is known of the drugs' interactions. The aim of this study was to analyse the effects of lithium, valproate, quetiapine and lamotrigine, and the interactions between them, on markers of inflammation, bioenergetics, mitochondrial function and oxidative stress in neuron-like cells (NT2) and microglial cells...
February 19, 2018: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29453686/antipsychotic-prescribing-and-safety-monitoring-practices-in-children-and-youth-a-population-based-study-in-alberta-canada
#7
Wenxin Chen, Monica Cepoiu-Martin, Antonia Stang, Diane Duncan, Chris Symonds, Lara Cooke, Tamara Pringsheim
BACKGROUND AND OBJECTIVE: Antipsychotic medication use has steadily increased in Canada, with an expansion in the profile of users and the diagnoses for which they are used. The use of antipsychotics is associated with a number of adverse effects for which routine monitoring is recommended. The objectives of this study were to determine the most common diagnoses associated with antipsychotic use in children in Alberta, Canada and the proportion who receive recommended laboratory tests for adverse effects...
May 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29449054/second-generation-antipsychotic-induced-mitochondrial-alterations-implications-for-increased-risk-of-metabolic-syndrome-in-patients-with-schizophrenia
#8
Giselli Scaini, João Quevedo, Dawn Velligan, David L Roberts, Henriette Raventos, Consuelo Walss-Bass
Metabolic syndrome (MetS) is seen more frequently in persons with schizophrenia than in the general population, and these metabolic abnormalities are further aggravated by second generation antipsychotic (SGA) drugs. Although the underlying mechanisms responsible for the increased prevalence of MetS among patients under SGA treatment are not well understood, alterations in mitochondria function have been implicated. We performed a comprehensive evaluation of the role of mitochondrial dysfunction in the pathophysiology of drug-induced MetS in schizophrenia...
March 2018: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29403139/quetiapine-induced-diabetic-ketoacidosis
#9
Soumitra Das, Dhanya S Palappallil, Arjun Kartha, Varun Rajan
Psychomotor retardation and extrapyramidal symptoms have limited the conventional antipsychotic use. Atypical antipsychotics though widely prescribed with good tolerability and efficacy, the metabolic complications associated with them are of clinical importance. Diabetic ketoacidosis (DKA) is a fatal complication of atypical antipsychotic use. We report a case of new-onset diabetes presenting as DKA with quetiapine use.
January 2018: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/29355909/risperidone-versus-other-antipsychotics-for-people-with-severe-mental-illness-and-co-occurring-substance-misuse
#10
REVIEW
Henk S Temmingh, Taryn Williams, Nandi Siegfried, Dan J Stein
BACKGROUND: Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI. OBJECTIVES: To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used in people with serious mental illness and co-occurring substance misuse...
January 22, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29331603/metabolic-risk-factors-in-schizophrenia-and-bipolar-disorder-the-effect-of-comedication-with-selective-serotonin-reuptake-inhibitors-and-antipsychotics
#11
K K Fjukstad, A Engum, S Lydersen, I Dieset, N Eiel Steen, O A Andreassen, O Spigset
BACKGROUND: The aim of this observational study was to investigate the relationship between metabolic factors and use of selective serotonin reuptake inhibitors (SSRIs) combined with olanzapine, quetiapine or risperidone. METHODS: Data from the Norwegian Thematically Organized Psychosis study, a cross-sectional study on 1301 patients with schizophrenia (n=868) or bipolar disorder (n=433), were analyzed. As exposure variables in the linear regression model were included the dose or serum concentration of SSRIs (n=280) and of olanzapine (n=398), quetiapine (n=234) or risperidone (n=128)...
February 2018: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/29133173/effects-of-norquetiapine-the-active-metabolite-of-quetiapine-on-cloned-herg-potassium-channels
#12
Hong Joon Lee, Jin-Sung Choi, Bok Hee Choi, Sang June Hahn
Quetiapine is an atypical antipsychotic drug that is widely used for the treatment of schizophrenia. It is mainly metabolized by a cytochrome P450 system in the liver. Norquetiapine is a major active metabolite in humans with a pharmacological profile that differs distinctly from that of quetiapine. We used the whole-cell patch-clamp technique to investigate the effects of norquetiapine on hERG channels that are stably expressed in HEK cells. Quetiapine and norquetiapine inhibited the hERG tail currents at -50mV in a concentration-dependent manner with IC50 values of 8...
January 18, 2018: Neuroscience Letters
https://www.readbyqxmd.com/read/29075885/long-term-metabolic-effects-of-aripiprazole-ziprasidone-and-quetiapine-a-pragmatic-clinical-trial-in-drug-na%C3%A3-ve-patients-with-a-first-episode-of-non-affective-psychosis
#13
Javier Vázquez-Bourgon, Rocío Pérez-Iglesias, Víctor Ortiz-García de la Foz, Paula Suárez Pinilla, Álvaro Díaz Martínez, Benedicto Crespo-Facorro
INTRODUCTION: The use of second-generation antipsychotics (SGA) has been associated with metabolic changes. However, there are differences in the metabolic profile between SGAs. We have previously observed that ziprasidone had a more benign early metabolic profile compared to aripiprazole and quetiapine. However, a long-term follow-up is preferred to detect clinically relevant impairment in metabolic parameters. We aimed to compare the effect of aripiprazole, ziprasidone, and quetiapine on metabolic measures in first-episode non-affective psychosis patients after 1 year of treatment...
January 2018: Psychopharmacology
https://www.readbyqxmd.com/read/28833962/biochemical-and-genetic-predictors-and-correlates-of-response-to-lamotrigine-and-folic-acid-in-bipolar-depression-analysis-of-the-cequel-clinical-trial
#14
E M Tunbridge, M J Attenburrow, A Gardiner, J M Rendell, C Hinds, G M Goodwin, P J Harrison, J R Geddes
OBJECTIVES: CEQUEL (Comparative Evaluation of QUEtiapine plus Lamotrigine combination versus quetiapine monotherapy [and folic acid versus placebo] in bipolar depression) was a double-blind, randomized, placebo-controlled, parallel group, 2×2 factorial trial that examined the effect of adding lamotrigine and/or folic acid (FA) to quetiapine in bipolar depression. Lamotrigine improved depression, but its effectiveness was reduced by FA. We investigated the baseline predictors and correlates of clinical response, and the possible basis of the interaction...
September 2017: Bipolar Disorders
https://www.readbyqxmd.com/read/28791693/atypical-antipsychotics-for-disruptive-behaviour-disorders-in-children-and-youths
#15
REVIEW
Jik H Loy, Sally N Merry, Sarah E Hetrick, Karolina Stasiak
BACKGROUND: This is an update of the original Cochrane Review, last published in 2012 (Loy 2012). Children and youths with disruptive behaviour disorders may present to health services, where they may be treated with atypical antipsychotics. There is increasing usage of atypical antipsychotics in the treatment of disruptive behaviour disorders. OBJECTIVES: To evaluate the effect and safety of atypical antipsychotics, compared to placebo, for treating disruptive behaviour disorders in children and youths...
August 9, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28730851/agomelatine-for-the-treatment-of-generalized-anxiety-disorder
#16
REVIEW
Massimiliano Buoli, Silvia Grassi, Marta Serati, A Carlo Altamura
Agomelatine is a melatonergic antidepressant, approved for the treatment of Major Depressive Disorder (MDD) in Europe and Australia, but not in the United States. This compound seems to be promising in the short-term and maintenance treatment of Generalized Anxiety Disorder (GAD). Areas covered: This paper presents an evaluation of the available data about the clinical efficacy and tolerability of agomelatine in the treatment of GAD. Expert opinion: First-line GAD treatments are limited by high rates of lack of clinical response...
September 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28721057/safety-tolerability-and-risks-associated-with-first-and-second-generation-antipsychotics-a-state-of-the-art-clinical-review
#17
REVIEW
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll, André F Carvalho
Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients - psychosocial functioning, quality of life, and recovery...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28703949/psychotherapy-alone-and-combined-with-medication-as-treatments-for-bipolar-ii-depression-a-randomized-controlled-trial
#18
Holly A Swartz, Paola Rucci, Michael E Thase, Meredith Wallace, Elisa Carretta, Karen L Celedonia, Ellen Frank
OBJECTIVE: Bipolar II disorder (BP-II) is associated with marked morbidity and mortality. Quetiapine, the treatment with greatest evidence for efficacy in BP-II depression, is associated with metabolic burden. Psychotherapy, a treatment with few side effects, has not been systematically evaluated in BP-II. This study compared psychotherapy plus placebo to psychotherapy plus pharmacotherapy as treatments for BP-II depression. METHODS: From 2010 to 2015, unmedicated adults (n = 92) with DSM-IV-TR BP-II depression were randomly assigned to weekly sessions of Interpersonal and Social Rhythm Therapy (IPSRT) plus placebo or IPSRT plus quetiapine and followed for 20 weeks...
March 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28636569/diabetic-ketoacidosis-associated-with-antipsychotic-drugs-case-reports-and-a-review-of-literature
#19
REVIEW
Antonia Vuk, Martina Rojnic Kuzman, Maja Baretic, Martina Matovinovic Osvatic
BACKGROUND: Second generation antipsychotics (SGAs) are associated with metabolic disturbances. Diabetic ketoacidosis (DKA) is a rare, but potentially fatal sign of acute glucose metabolism dysregulation linked to the use of SGAs. The aims of this article are to present patients with a history of psychotic disorders and of severe metabolic diabetic ketoacidosis, possibly associated with the use of antipsychotics, and to review the current literature on the topic of antipsychotic-induced DKA...
June 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28599949/quetiapine-extended-release-versus-aripiprazole-in-children-and-adolescents-with-first-episode-psychosis-the-multicentre-double-blind-randomised-tolerability-and-efficacy-of-antipsychotics-tea-trial
#20
Anne Katrine Pagsberg, Pia Jeppesen, Dea Gowers Klauber, Karsten Gjessing Jensen, Ditte Rudå, Marie Stentebjerg-Olesen, Peter Jantzen, Simone Rasmussen, Eva Ann-Sofie Saldeen, Maj-Britt Glenn Lauritsen, Niels Bilenberg, Anne Dorte Stenstrøm, Louise Nyvang, Sarah Madsen, Thomas M Werge, Theis Lange, Christian Gluud, Maria Skoog, Per Winkel, Jens Richardt M Jepsen, Birgitte Fagerlund, Christoph U Correll, Anders Fink-Jensen
BACKGROUND: Head-to-head trials to guide antipsychotic treatment choices for paediatric psychosis are urgently needed because extrapolations from adult studies might not be implementable. In this superiority trial with two-sided significance testing, we aimed to compare the efficacy and safety of quetiapine-extended release (quetiapine-ER) versus aripiprazole in children and adolescents with first-episode psychosis, to determine whether differences between the two treatments were sufficient to guide clinicians in their choice of one drug over the other...
August 2017: Lancet Psychiatry
keyword
keyword
119251
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"